glp-1 without diabetes Receptor Agonists Linked to Reduced Asthma Exacerbations in Overweight and Obese Adults Optimizing GLP-1 therapies for obesity

In 1987 he and Bernhard Kreymann launched a study with other colleagues to investigate the physiological effect of another synthesised fragment of human GLP-1 directly in humans

J., Imbens, G

Concerns about the potential association between certain diabetes medications and cardiovascular disease meant that in 2010 the FDA approved liraglutide on condition that Novo Nordisk conduct a post-marketing study to evaluate the drug's effect on the incidence of major cardiovascular events (Nielsen, DeChiaro, Goldman)

Cardiovascular and Kidney Effects Trend Net Positive Over Years The longer-term picture is not uniformly cautionary

Written by Rachel Kim, MS, RD , Registered Dietitian & Health Writer Medically reviewed by FormBlends Clinical Review , Clinical Pharmacist & Medical Reviewer Published: Key Takeaway Compare semaglutide vs Contrave for weight loss

Lancet 402 , 429431 (2023)